Everest Medicines Limited
Everest Medicines Limited, a biopharmaceutical company, engages in discovery, licensing, clinical development, and commercialization of therapies to address critical unmet medical needs in Greater China and other Asia Pacific markets. Its pipeline produc…
Biotechnology
CN, Shanghai [HQ]
FA
Fundamental Analysis · Most Recent Quarter
A dedicated fundamental analysis might help you to get a quick overview
of the
financial stability. It is important to understand the
FA Algorithm
and the criterias before valuing it as a top-tier resource.
1
Financial Health
| Metric | Q3 | Q4 | Δ in % | |
|---|---|---|---|---|
| Current Ratio | 0.00 | 8.36 | 8.36 | |
| Debt/Assets | n.A. | n.A. | n.A. | |
| Debt/Equity | n.A. | n.A. | n.A. | |
| Net Debt/EBITDA | 402.51 | 0.06 | 0.01 | |
| Naive Interpretation | member | |||
2
Per Share
| Metric | Q3 | Q4 | Δ in % | |
|---|---|---|---|---|
| Book Value | 0.00 | 15.39 | 15.39 | |
| Cash | 0.00 | 7.28 | 7.28 | |
| Capex | 0.00 | -0.07 | -0.07 | |
| Free Cash Flow | 0.00 | -0.58 | -0.58 | |
| Revenue | 0.00 | 0.18 | 0.18 | |
| Naive Interpretation | member | |||
3
Profitability
| Metric | Q3 | Q4 | Δ in % | |
|---|---|---|---|---|
| Gross Margin | 0.00 | 0.73 | 0.73 | |
| Operating Margin | 0.00 | -3.62 | -3.62 | |
| ROA | 0.00 | -0.04 | -0.04 | |
| ROE | 0.00 | -0.04 | -0.04 | |
| ROIC | -0.18 | -0.04 | -0.04 | |
| Naive Interpretation | member | |||
4
Valuation
The "Valuation Entry" for the Focus of 1952.HK is permitted for members.
5
Growth
The "Growth Entry" for the Focus of 1952.HK is permitted for members.
6
Leverage & Liquidity